FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2527863729> ?p ?o ?g. }

• W2527863729 endingPage "541" @default.
• W2527863729 startingPage "534" @default.
• W2527863729 abstract "Major changes have emerged during the last few years in the therapy of chronic HCV. Several direct acting antiviral agents have been developed showing potent activity with higher rates of sustained virological response, even in difficult-to-treat patients. This study explores real life experience concerning efficacy, safety and possible predictors of response for the first cohort of Egyptian patients with chronic HCV genotype IV treated with Sofosbuvir/Simprevir combination therapy.This real life study recruited the first (6211) chronic HCV genotype IV Egyptian patients, who received antiviral therapy in viral hepatitis specialized treatment centres affiliated to the National committee for control of viral hepatitis. All enrolled patients received 12 weeks course of daily combination of sofosbuvir (400 mg) and simeprevir (150 mg). Patients were closely monitored for treatment safety and efficacy.Overall sustained virological response 12 rate was 94.0% while the end of treatment response rate was 97.6%. sustained virological response 12 rates in easy and difficult-to-treat groups were 96% and 93% respectively. Univariate and multivariate logistic regression analysis revealed significant association of low albumin (<3.5), cirrhosis and Fib-4 score (>3.25) with treatment failure. Fatal adverse events occurred in 23/6211 cases (0.37%) due to liver cell failure adverse events or SAEs leading to treatment discontinuation occurred in 97 patients (1.6%).Sofosbuvir/Simeprevir combination is an effective and well tolerated regimen for patients with chronic HCV genotype IV." @default.
• W2527863729 created "2016-10-14" @default.
• W2527863729 creator A5005157194 @default.
• W2527863729 creator A5011520858 @default.
• W2527863729 creator A5014616468 @default.
• W2527863729 creator A5017728760 @default.
• W2527863729 creator A5028056103 @default.
• W2527863729 creator A5037906942 @default.
• W2527863729 creator A5044453528 @default.
• W2527863729 creator A5048638161 @default.
• W2527863729 creator A5054383958 @default.
• W2527863729 creator A5056024488 @default.
• W2527863729 creator A5058546115 @default.
• W2527863729 creator A5060148481 @default.
• W2527863729 creator A5061692975 @default.
• W2527863729 creator A5067279761 @default.
• W2527863729 creator A5070308910 @default.
• W2527863729 creator A5071505004 @default.
• W2527863729 creator A5072014617 @default.
• W2527863729 creator A5083287436 @default.
• W2527863729 creator A5084756699 @default.
• W2527863729 creator A5085668597 @default.
• W2527863729 date "2016-11-04" @default.
• W2527863729 modified "2023-10-02" @default.
• W2527863729 title "Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients" @default.
• W2527863729 cites W1821706753 @default.
• W2527863729 cites W1984940447 @default.
• W2527863729 cites W1992221942 @default.
• W2527863729 cites W2010380636 @default.
• W2527863729 cites W2014487071 @default.
• W2527863729 cites W2019722329 @default.
• W2527863729 cites W2037648619 @default.
• W2527863729 cites W2064387090 @default.
• W2527863729 cites W2068705922 @default.
• W2527863729 cites W2124273275 @default.
• W2527863729 cites W2126689013 @default.
• W2527863729 cites W2155431764 @default.
• W2527863729 cites W2164466220 @default.
• W2527863729 cites W2343519173 @default.
• W2527863729 cites W2410976255 @default.
• W2527863729 cites W2417431402 @default.
• W2527863729 cites W2474550774 @default.
• W2527863729 doi "https://doi.org/10.1111/liv.13266" @default.
• W2527863729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27712017" @default.
• W2527863729 hasPublicationYear "2016" @default.
• W2527863729 type Work @default.
• W2527863729 sameAs 2527863729 @default.
• W2527863729 citedByCount "50" @default.
• W2527863729 countsByYear W25278637292016 @default.
• W2527863729 countsByYear W25278637292017 @default.
• W2527863729 countsByYear W25278637292018 @default.
• W2527863729 countsByYear W25278637292019 @default.
• W2527863729 countsByYear W25278637292020 @default.
• W2527863729 countsByYear W25278637292021 @default.
• W2527863729 countsByYear W25278637292022 @default.
• W2527863729 crossrefType "journal-article" @default.
• W2527863729 hasAuthorship W2527863729A5005157194 @default.
• W2527863729 hasAuthorship W2527863729A5011520858 @default.
• W2527863729 hasAuthorship W2527863729A5014616468 @default.
• W2527863729 hasAuthorship W2527863729A5017728760 @default.
• W2527863729 hasAuthorship W2527863729A5028056103 @default.
• W2527863729 hasAuthorship W2527863729A5037906942 @default.
• W2527863729 hasAuthorship W2527863729A5044453528 @default.
• W2527863729 hasAuthorship W2527863729A5048638161 @default.
• W2527863729 hasAuthorship W2527863729A5054383958 @default.
• W2527863729 hasAuthorship W2527863729A5056024488 @default.
• W2527863729 hasAuthorship W2527863729A5058546115 @default.
• W2527863729 hasAuthorship W2527863729A5060148481 @default.
• W2527863729 hasAuthorship W2527863729A5061692975 @default.
• W2527863729 hasAuthorship W2527863729A5067279761 @default.
• W2527863729 hasAuthorship W2527863729A5070308910 @default.
• W2527863729 hasAuthorship W2527863729A5071505004 @default.
• W2527863729 hasAuthorship W2527863729A5072014617 @default.
• W2527863729 hasAuthorship W2527863729A5083287436 @default.
• W2527863729 hasAuthorship W2527863729A5084756699 @default.
• W2527863729 hasAuthorship W2527863729A5085668597 @default.
• W2527863729 hasConcept C126322002 @default.
• W2527863729 hasConcept C197934379 @default.
• W2527863729 hasConcept C203014093 @default.
• W2527863729 hasConcept C2522874641 @default.
• W2527863729 hasConcept C2776408679 @default.
• W2527863729 hasConcept C2776455275 @default.
• W2527863729 hasConcept C2777214474 @default.
• W2527863729 hasConcept C2778390639 @default.
• W2527863729 hasConcept C2778715236 @default.
• W2527863729 hasConcept C2778986448 @default.
• W2527863729 hasConcept C2780040827 @default.
• W2527863729 hasConcept C2781413609 @default.
• W2527863729 hasConcept C71924100 @default.
• W2527863729 hasConcept C90924648 @default.
• W2527863729 hasConceptScore W2527863729C126322002 @default.
• W2527863729 hasConceptScore W2527863729C197934379 @default.
• W2527863729 hasConceptScore W2527863729C203014093 @default.
• W2527863729 hasConceptScore W2527863729C2522874641 @default.
• W2527863729 hasConceptScore W2527863729C2776408679 @default.
• W2527863729 hasConceptScore W2527863729C2776455275 @default.
• W2527863729 hasConceptScore W2527863729C2777214474 @default.
• W2527863729 hasConceptScore W2527863729C2778390639 @default.

• next